Skip to main content
Clinical Trials/NCT03817372
NCT03817372CompletedNot Applicable

Comparison of Anterior-Posterior Versus Anterior-Lateral Electrode Position in Cardioverting Atrial Fibrillation - A Randomized Clinical Trial

University of Aarhus6 sites in 1 country468 target enrollmentStarted: February 19, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
468
Locations
6
Primary Endpoint
Efficacy: First shock success

Study Overview

Brief Summary

Atrial fibrillation is the most common heart rhythm disorder, and the incidence is rapidly increasing. Cardioversion using an electrical shock (DC-cardioversion) is an important treatment to reduce symptoms and improve patient's quality-of-life. The treatment is performed by applying gel electrodes to the chest. Cardioversion is not always successful, and it is unknown which electrode-position provides the optimal efficacy.

This study aims to compare two electrode positions, which are in clinical use: Anterior-posterior (left front and left back) versus anterior-lateral (right front and left side of the chest).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Atrial fibrillation (documented on an ECG-12)
  • Able and willing to sign informed consent
  • Age ≥ 18 years
  • Anticoagulation according to guidelines (Patients with atrial fibrillation for >48 hours will be required to have a documented weekly international normalized ratio (INR) ≥2.0 (including within 48 hours of cardioversion) or treatment with non-vitamin K oral anticoagulant for three weeks or longer. Alternatively, a transoesophageal echocardiogram documenting the absence of intracardiac thrombi is accepted and cardioversion can be performed on treatment with low molecular weight heparin).

Exclusion Criteria

  • Implanted pacemaker and/or cardioverter defibrillator (ICD)
  • Prior enrollment in the trial
  • Hemodynamically unstable atrial fibrillation
  • Untreated hyperthyroidism
  • Known or suspected pregnancy

Outcomes

Primary Outcomes

Efficacy: First shock success

Time Frame: Immediately after first cardioversion attempt.

The primary endpoint will be first shock efficacy, i.e. the proportion of patients in sinus rhythm for at least one minute immediately after an initial shock of 100 J.

Secondary Outcomes

  • Safety: Number of participants with skin-discomfort, skin burns or itching(Two hours after cardioversion (at discharge))
  • Efficacy: Successful cardioversion(One minute after cardioversion)
  • Safety: Number of participants with arrhythmic events during and after cardioversion(Within 2 hours after cardioversion (until discharge))

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (6)

Loading locations...

Similar Trials